Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR142 | Q7Z601 | 14/20 | 1.00 |
| ▸ | ABL1 | P00519 | 3/20 | 0.50 |
| ▸ | BCR | P11274 | 3/20 | 0.50 |
| ▸ | BRAF | P15056 | 2/20 | 0.46 |
| ▸ | MLLT1 | Q03111 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21615154 | 0.87 | GPR142 (1.00) | GPR142ABL1BCRBRAF | |
| SCHEMBL21615150 | 0.86 | GPR142 (1.00) | GPR142 | |
| SCHEMBL21615099 | 0.86 | GPR142 (1.00) | GPR142ABL1BCRBRAF | |
| SCHEMBL21611777 | 0.80 | GPR142 (0.66) | GPR142BRAF | |
| SCHEMBL21615071 | 0.79 | GPR142 (0.66) | GPR142BRAF | |
| SCHEMBL21615092 | 0.78 | GPR142 (1.00) | GPR142 | |
| SCHEMBL24040819 | 0.75 | GPR142 (1.00) | GPR142 | |
| SCHEMBL21615090 | 0.75 | GPR142 (1.00) | GPR142 | |
| SCHEMBL24040820 | 0.74 | GPR142 (1.00) | GPR142BRAF | |
| SCHEMBL24040795 | 0.74 | GPR142 (1.00) | GPR142BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11179371-B2 | Triazole benzamide derivatives as GPR142 agonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-11-23 | — | — | US | disclosed |
| WO-2020007729-A1 | TRIAZOLE BENZAMIDE DERIVATIVES AS GPR142 AGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11179371-B2 | Triazole benzamide derivatives as GPR142 agonists | GPR119, GPR142, GPR65 | GPR142 2/4885ABL1 2579/4885BCR 1657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.